Literature DB >> 18760706

Treatment of follicular non-Hodgkin's lymphoma: the old and the new.

Jonathan W Friedberg1.   

Abstract

Despite remaining an incurable disease, overall survival improvements have been noted in patients with advanced-stage follicular lymphoma. The Follicular Lymphoma International Prognostic Index (FLIPI) is a robust prognostic index in this disease, and continues to provide prognostic information in the rituximab era. Rituximab has significantly changed the management of follicular lymphoma, and the most dramatic impact of rituximab is observed in combination with cytotoxic chemotherapy. However, resistance to rituximab remains a problem, and standard therapy in the rituximab-refractory setting includes radioimmunotherapy, autologous stem cell transplantation, and allogeneic stem cell transplantation. In addition, several novel agents show encouraging activity in follicular lymphoma, including bendamustine, lenalidomide, bortezomib, and other proteasome inhibitors, and BCL2 inhibitors.

Entities:  

Mesh：

Year:  2008        PMID： 18760706      PMCID： PMC2597584          DOI： 10.1053/j.seminhematol.2008.07.003

Source DB:  PubMed          Journal:  Semin Hematol        ISSN： 0037-1963            Impact factor:   3.851


  23 in total

Review 1.  How Avastin potentiates chemotherapeutic drugs: action and reaction in antiangiogenic therapy.

Authors:  Mikhail V Blagosklonny
Journal:  Cancer Biol Ther       Date:  2005-12-11       Impact factor: 4.742

2.  Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.

Authors:  Susan D Demo; Christopher J Kirk; Monette A Aujay; Tonia J Buchholz; Maya Dajee; Mark N Ho; Jing Jiang; Guy J Laidig; Evan R Lewis; Francesco Parlati; Kevin D Shenk; Mark S Smyth; Congcong M Sun; Marcy K Vallone; Tina M Woo; Christopher J Molineaux; Mark K Bennett
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

3.  A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.

Authors:  D Chauhan; M Velankar; M Brahmandam; T Hideshima; K Podar; P Richardson; R Schlossman; I Ghobrial; N Raje; N Munshi; K C Anderson
Journal:  Oncogene       Date:  2006-10-02       Impact factor: 9.867

Review 4.  Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma.

Authors:  Owen A O'Connor
Journal:  Clin Lymphoma Myeloma       Date:  2005-11

5.  The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome.

Authors:  Christian Buske; Eva Hoster; Martin Dreyling; Joerg Hasford; Michael Unterhalt; Wolfgang Hiddemann
Journal:  Blood       Date:  2006-05-11       Impact factor: 22.113

Review 6.  New directions in the treatment of mantle cell lymphoma: an overview.

Authors:  Andre Goy
Journal:  Clin Lymphoma Myeloma       Date:  2006-10

7.  Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.

Authors:  Thomas E Witzig; Ian W Flinn; Leo I Gordon; Christos Emmanouilides; Myron S Czuczman; Mansoor N Saleh; Larry Cripe; Gregory Wiseman; Teresa Olejnik; Pratik S Multani; Christine A White
Journal:  J Clin Oncol       Date:  2002-08-01       Impact factor: 44.544

8.  Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up.

Authors:  Ama Z S Rohatiner; Lee Nadler; Andrew J Davies; John Apostolidis; Donna Neuberg; Janet Matthews; John G Gribben; Peter M Mauch; T Andrew Lister; Arnold S Freedman
Journal:  J Clin Oncol       Date:  2007-05-21       Impact factor: 44.544

Review 9.  Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.

Authors:  John P Leonard; Richard R Furman; Morton Coleman
Journal:  Int J Cancer       Date:  2006-09-01       Impact factor: 7.396

10.  Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.

Authors:  Jonathan W Friedberg; Philip Cohen; Ling Chen; K Sue Robinson; Andres Forero-Torres; Ann S La Casce; Luis E Fayad; Alberto Bessudo; Elber S Camacho; Michael E Williams; Richard H van der Jagt; Jennifer W Oliver; Bruce D Cheson
Journal:  J Clin Oncol       Date:  2008-01-10       Impact factor: 44.544
View more
  12 in total

Review 1.  Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment.

Authors:  Cristina Correia; Sun-Hee Lee; X Wei Meng; Nicole D Vincelette; Katherine L B Knorr; Husheng Ding; Grzegorz S Nowakowski; Haiming Dai; Scott H Kaufmann
Journal:  Biochim Biophys Acta       Date:  2015-03-27

2.  Inherited genetic variation and overall survival following follicular lymphoma.

Authors:  Todd M Gibson; Sophia S Wang; James R Cerhan; Matthew J Maurer; Patricia Hartge; Thomas M Habermann; Scott Davis; Wendy Cozen; Charles F Lynch; Richard K Severson; Nathaniel Rothman; Stephen J Chanock; Lindsay M Morton
Journal:  Am J Hematol       Date:  2012-03-31       Impact factor: 10.047

3.  Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.

Authors:  Ronald Levy; Kristen N Ganjoo; John P Leonard; Julie M Vose; Ian W Flinn; Richard F Ambinder; Joseph M Connors; Neil L Berinstein; Andrew R Belch; Nancy L Bartlett; Craig Nichols; Christos E Emmanouilides; John M Timmerman; Stephanie A Gregory; Brian K Link; David J Inwards; Arnold S Freedman; Jeffrey V Matous; Michael J Robertson; Lori A Kunkel; Diane E Ingolia; Andrew J Gentles; Chih Long Liu; Robert Tibshirani; Ash A Alizadeh; Dan W Denney
Journal:  J Clin Oncol       Date:  2014-05-05       Impact factor: 44.544

4.  Mechanisms regulating enhanced human leukocyte antigen class II-mediated CD4 + T cell recognition of human B-cell lymphoma by resveratrol.

Authors:  Faisal F Y Radwan; Lixia Zhang; Azim Hossain; Bently P Doonan; Jason M God; Azizul Haque
Journal:  Leuk Lymphoma       Date:  2011-10-24

5.  Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.

Authors:  Michael S van der Veer; Michel de Weers; Berris van Kessel; Joost M Bakker; Shulamiet Wittebol; Paul W H I Parren; Henk M Lokhorst; Tuna Mutis
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

6.  Coping with non-Hodgkin's lymphoma: a qualitative study of patient perceptions and supportive care needs whilst undergoing chemotherapy.

Authors:  Daren Chircop; Josianne Scerri
Journal:  Support Care Cancer       Date:  2017-02-23       Impact factor: 3.603

Review 7.  Effects on bone metabolism of new therapeutic strategies with standard chemotherapy and biologic drugs.

Authors:  Stefania Ciolli
Journal:  Clin Cases Miner Bone Metab       Date:  2013-09

Review 8.  Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs).

Authors:  Peter H Wiernik
Journal:  Curr Treat Options Oncol       Date:  2008-11-19

Review 9.  Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside.

Authors:  Anthony R Mato; Tatyana Feldman; André Goy
Journal:  Oncologist       Date:  2012-05-07

10.  Metastatic seminoma and grade 1 follicular lymphoma presenting concurrently in a supraclavicular lymph node: a case report.

Authors:  Eric Jacobsen; Jey-Hsin Chen; Brian Schurko; Carol Benson; William K Oh
Journal:  Cases J       Date:  2009-08-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.